GLP-1 telehealth brands and websites named in FDA warning letters

Which GLP-1 telehealth websites has FDA named in warning letters?

As of Nov 15, 2026, all 111 FDA GLP-1 warning letters to telehealth companies in this index name the company’s website, and 141 websites appear across all 155 letters, including tryeden.com (Eden Health International Inc. dba Eden, Jun 8, 2026), ivimhealth.com (Ivim Services LLC dba Ivim, Feb 20, 2026) and hims.com (Hims & Hers Health, Inc. dba Hims, Sep 9, 2025). The table matches each website to the legal name FDA addressed.

Website addresses are copied from the letter text on fda.gov. A website missing here has not been named in a GLP-1 warning letter in this index; that is not a finding about it.

Letter
24hrdoc.com24HrDoc, Inc. dba 24HrDocTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.24hrdoc.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
24hreup.bizwww.24hreup.bizOnline sellerApr 23, 2025Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet
The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet addresses www.24hreup.biz and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …”
fda.gov
24hreup.comwww.24hreup.bizOnline sellerApr 23, 2025Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet
The letter’s words: “We advise you to review your websites (including www.24hreup.com which forwards to www.24hreup.biz), product labels, and other labeling and promotional materials to ensure that you are not misleadingly …”
fda.gov
alanmeds.comAlan Health Technologies Inc. dba AlanTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.alanmeds.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
all-american-wellness.comAll American WellnessTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://all-american-wellness.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
altrutelehealth.comAltru Telehealth, LLC dba Altru TelehealthTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Altru Telehealth’s website, https://altrutelehealth.com, FDA Establishment Identifier (FEI) 3044020130, in March 2026.”
fda.gov
altrx.comTrinity HealthCare Supply, LLC dba altRxTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of altRx’s website, https://www.altrx.com, FDA Establishment Identifier (FEI) 3044175714, in May 2026.”
fda.gov
amazing-meds.comAmazing MedsTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://amazing-meds.com in August 2025 and has observed that your website offers various compounded drug products, including retatrutide and semaglutide.”
fda.gov
anumed-intl.comAnuMed International, LLCNot statedAug 20, 2024Finished Pharmaceutical/Unapproved New Drug/Adulterated/Misbranded
The letter’s words: “FDA also reviewed your website at the Internet address https://www.anumed-intl.com/ in February and April 2024 and has observed that your website offers “Semaglutide Homeopathic Formula,” “Magnesium 50 mg Body Cream,” …”
fda.gov
asn-labs.comASN-LABSTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://asn-labs.com in August 2025 and has observed that your website offers various compounded drug products, including retatrutide and semaglutide.”
fda.gov
bluefitmd.comBluefitMDTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.bluefitmd.com/, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
bodygoodstudio.comBody Good StudioTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.bodygoodstudio.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
buynetmeds.comwww.buynetmeds.comOnline sellerJun 12, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet
The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.buynetmeds.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …”
fda.gov
canadamedstop.comCanada Med StopTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.canadamedstop.com in August 2025 and has observed that your website offers compounded semaglutide drug products.”
fda.gov
cheapmedicineshop.comCheap Medicine Shop/www.cheapmedicineshop.comInternet pharmacySep 24, 2026Unapproved New Drugs/Misbranded (Internet Pharmacy)
The letter’s words: “Food and Drug Administration (FDA) review of your website www.cheapmedicineshop.com.”
fda.gov
cheaptrustedpharmacy.comcheaptrustedpharmacy.comOnline sellerJul 29, 2025Notice of Unlawful Sale of Unapproved Drugs to United States Consumers Over the Internet
The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.cheaptrustedpharmacy.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …”
fda.gov
clovermeds.comClover Meds LLC dba Clover MedsTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Clover Meds’ website, https://clovermeds.com, FDA Establishment Identifier (FEI) 3044175705, in March 2026.”
fda.gov
coretrustlabs.comEA WORKS Limited Liability Company dba Trust LabsTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://coretrustlabs.com in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide.”
fda.gov
cosmomedspa.comCosmo Medical Spa dba Cosmo Med SpaTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://cosmomedspa.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
dashpct.comwww.dashpct.comOnline sellerApr 24, 2024Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet
The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.dashpct.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …”
fda.gov
deluxeivaesthetics.comDeluxe IV Aesthetics PLLC dba Deluxe IV and AestheticsTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://deluxeivaesthetics.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
dhmedicalcenter.comD&H Medical ServicesTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of D&H Medical Services’ website, https://www.dhmedicalcenter.com, FDA Establishment Identifier (FEI) 3044174854, in March 2026.”
fda.gov
directmeds.comdirectmeds.com, Inc. dba DirectMedsTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://directmeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
drgatergetsresults.comDr. Gater’s Weight Loss & WellnessTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://drgatergetsresults.com in September 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
drjennpb.comMedClub by Dr. JennTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://drjennpb.com in June 2025 and has observed that your website offers various compounded drug products, including retatrutide and semaglutide.”
fda.gov
drmedhealth.comPublic Health Solution LLC dba DrMedHealthTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of DrMedHealth’s website, https://drmedhealth.com, FDA Establishment Identifier (FEI) 3044020737, in March 2026.”
fda.gov
edrugstore.comeDrugstoreTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.edrugstore.com in August 2025 and has observed that your website offers various compounded drug products, including tirzepatide.”
fda.gov
elevatedhealth.comElevate Your Wellness LLC, dba ElevatedTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://elevatedhealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
eliterapidfatloss.comElite Health CenterTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://eliterapidfatloss.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
erasingage.comExpert AestheticsTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://erasingage.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
evolifewellness.comEvoLife WellnessTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://evolifewellness.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
fancymeds.comFancy Meds, LLC dba Fancy MedsTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://fancymeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
fifty410.comAspen Aesthetics dba Fifty 410TelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.fifty410.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
fitish.comFITISHTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of FITISH’s website, https://fitish.com, FDA Establishment Identifier (FEI) 3044018836, in March 2026.”
fda.gov
fitrxapp.comFitRX, LLC dba FitRxTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.fitrxapp.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
forhers.comHims & Hers Health, Inc. dba HersTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.forhers.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
fwd.careFWD Care, Inc. dba FWDTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://fwd.care in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
genlabmeds.comGenLabMedsTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://genlabmeds.com in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide, and tirzepatide.”
fda.gov
getamrx.comFitRX, LLC dba AM RXTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of AM RX’s website, https://getamrx.com, FDA Establishment Identifier (FEI) 3044021238, in March 2026.”
fda.gov
getcurex.comCurexTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://getcurex.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
getfitmedical.comGet.Fit.Medical, LLC dba Get.Fit.MedicalTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “… letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.getfitmedical.com in August 2025 and has observed that your website offers various compounded drug products, including sildenafil, tadalafil, semaglutide, …”
fda.gov
getzealthy.comFitRX, LLC dba ZealthyTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.getzealthy.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
getzeuss.comZeuss LLC dba ZeussTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://getzeuss.com/, in December 2025, and has observed that your website offers compounded drug products, including tirzepatide drug products.”
fda.gov
glp1solution.storeGLP-1 SolutionTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://glp1solution.store in August 2025 and has observed that your website offers various compounded drug products, including retatrutide, semaglutide and tirzepatide.”
fda.gov
gobioverse.comBioverse, Inc. dba BioverseTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.gobioverse.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
goodgirlrx.comGood Girl LLC dba GoodGirlRXTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://goodgirlrx.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
gorillahealing.comwww.gorillahealing.comNot statedOct 2, 2023Finished Pharmaceuticals/Unapproved New Drug/Misbranded
The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.gorillahealing.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …”
fda.gov
grampeptides.comGram PeptidesOnline sellerMar 31, 2026Unapproved New Drugs Sold Over the Internet
The letter’s words: “Food and Drug Administration (FDA) reviewed your website at https://grampeptides.com from January to March 2026.”
fda.gov
harpermeds.comNexus Health Solutions LLC dba Harper MedsTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Harper Meds’ website, https://www.harpermeds.com, FDA Establishment Identifier (FEI) 3044020867, in March 2026.”
fda.gov
healberry.comHealBerryTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://healberry.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
healthon.comHealthon Inc. dba HealthonTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://healthon.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
healthyliving.clinicHealthy Living ClinicTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://healthyliving.clinic in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
healthymale.comHealthy MaleTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://healthymale.com in August 2025 and has observed that your website offers various compounded drug products, including tirzepatide.”
fda.gov
helixchem.comSynthetix Inc. DBA Helix Chemical SupplyNot statedFeb 7, 2024Unapproved New Drugs/Misbranded
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.helixchem.com in October 2023 and has observed that your website offers “Semaglutide” and “Tirzepatide” products for sale in the United States.”
fda.gov
hims.comHims & Hers Health, Inc. dba HimsTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.hims.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
hydramed.comHydraMed IV LLC dba HydraMedTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of HydraMed’s website, https://hydramed.com, FDA Establishment Identifier (FEI) 3044021141, in March 2026.”
fda.gov
inspire.clinicinspire.clinicTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “Center for Drug Evaluation and Research (CDER) United States WARNING LETTER September 9, 2025 inspire.clinic: This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet …”
fda.gov
intimaterose.comIntimate RoseTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.intimaterose.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
invigoratemedspa.comInvigorate Med SpaTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://invigoratemedspa.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
ivimhealth.comIvim Services LLC dba IvimTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.ivimhealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
ivisitdoc.comiVisitDoc, Inc. dba iVisitDocTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “… letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://ivisitdoc.com in August 2025 and has observed that your website offers various compounded semaglutide drug products.1 As described below, your claims …”
fda.gov
joiandblokes.comJoi and Blokes dba Joi + BlokesTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Joi + Blokes’ website, https://joiandblokes.com, FDA Establishment Identifier (FEI) 3044021205, in March 2026.”
fda.gov
joinbelle.comBelle Health LLC dba BelleTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.joinbelle.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
joinbliv.comBliv Wellness LLC dba BlivTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.joinbliv.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
joinezra.comEzra Holdco LLC dba EzraTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Ezra’s website, https://joinezra.com, FDA Establishment Identifier (FEI) 3045074898, in May 2026.”
fda.gov
joinjosie.comJoin JosieTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://joinjosie.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
joinlevity.comLevity Inc. dba LevityTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.joinlevity.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and liraglutide drug products.”
fda.gov
joinsprouthealth.comSprout Health Partners LLC dba Sprout HealthTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://joinsprouthealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
joinweightcare.comWeightless Medical LLC dba WeightCareTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://joinweightcare.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
julymd.comJulyMDTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://julymd.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
kinmeds.comKin MedsTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://kinmeds.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
leandreamsweightloss.comLean Dreams LLC dba LeanDreamsTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.leandreamsweightloss.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
lovelymeds.comLovely Meds, Inc. dba Lovely MedsTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.lovelymeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
lumimeds.comLumimedsTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://lumimeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
maneandsteel.comMane & Steel, LLC. dba Mane & SteelTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://maneandsteel.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
master-pharmaceuticals.comMaster Pharmaceuticals GroupTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.master-pharmaceuticals.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
maximustribe.comMaximus Health, Inc. dba MaximusTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Maximus’ website, https://www.maximustribe.com, FDA Establishment Identifier (FEI) 3032037948, in May 2026.”
fda.gov
maxlife.comMaxLife Technologies Inc. dba MaxlifeTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://maxlife.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
medicaweightloss.comMedica Weight LossTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Medica Weight Loss’ website, https://medicaweightloss.com, FDA Establishment Identifier (FEI) 3044019522, in March 2026.”
fda.gov
medvi.ioMEDVi, LLC dba MEDViTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://medvi.io, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
mintmed.comGlow Medispa, LLC dba Mint MedTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Mint Med’s website, https://mintmed.com, FDA Establishment Identifier (FEI) 3044896930, in May 2026.”
fda.gov
momentumhealth360.comMomentum Health 360 dba Momentum HealthTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Momentum Health’s website, https://momentumhealth360.com, FDA Establishment Identifier (FEI) 3043997131, in March 2026.”
fda.gov
motionpharmacy.commotionpharmacy.comNot statedSep 10, 2025Unapproved New Drug/Misbranded
The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.motionpharmacy.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …”
fda.gov
myamphealth.comDripgym Mobile Parent, LLC dba Amp HealthTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “… letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://myamphealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug …”
fda.gov
mystarthealth.comMatthew Stern, CEO MyStart Health LLC.TelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.mystarthealth.com in August 2025 and has observed that your website offers compounded semaglutide.”
fda.gov
nativemed.netNativeMed LLC dba NativeMedTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of NativeMed’s website, https://www.nativemed.net, FDA Establishment Identifier (FEI) 3044024130, in March 2026.”
fda.gov
newmanclinic.comNewman Clinic, PLLC dba Newman ClinicTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.newmanclinic.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
newself.comNewSelf Limited dba NewSelfTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.newself.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
nexlife.usNexlife Inc. dba NexlifeTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Nexlife’s website, https://nexlife.us, FDA Establishment Identifier (FEI) 3044820290, in March 2026.”
fda.gov
nomida.bizNomida.bizNot statedSep 12, 2024Unapproved New Drugs/Misbranded
The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.nomida.biz and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …”
fda.gov
novarx.coNova Vascular LLC dba NOVARXTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of NOVARX’s website, https://novarx.co, FDA Establishment Identifier (FEI) 3044022416, in March 2026.”
fda.gov
nusciencepeptides.comNuScience Peptides LLCNot statedAug 24, 2026Unapproved New Drugs/Misbranded
The letter’s words: “FDA Review Violations were identified and documented during a review of your website nusciencepeptides.com in July 2026.”
fda.gov
nuvolifehealth.comNuvo Life Health Inc. dba Nuvo Life HealthTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://nuvolifehealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
onlinegenericmedicine.comOnline Generic Medicine/www.onlinegenericmedicine.comInternet pharmacySep 23, 2026Unapproved New Drug/Misbranded (Internet Pharmacy)
The letter’s words: “Food and Drug Administration (FDA) review of your website www.onlinegenericmedicine.com.”
fda.gov
orderlymeds.comOrderlyMeds LLC dba OrderlyMedsTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of OrderlyMeds’ website, https://orderlymeds.com, FDA Establishment Identifier (FEI) 3044027176, in March 2026.”
fda.gov
ozempen.comOzempen.comOnline sellerJun 24, 2024Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet
The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.ozempen.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …”
fda.gov
peacefulmeds.comwww.peacefulmeds.comOnline sellerMay 5, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet
The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.peacefulmeds.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …”
fda.gov
peakscurative.comPeaks Curative, LLC dba PeaksTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://peakscurative.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide drug products.”
fda.gov
pekcuralabs.comPekCura LabsOnline sellerMar 31, 2026Unapproved New Drugs Sold Over the Internet
The letter’s words: “Food and Drug Administration (FDA) reviewed your website at https://pekcuralabs.com/ in January 2026.”
fda.gov
pharmazee.coPharmaZeeTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://pharmazee.co, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
pinkponypeptides.comLovega LLC dba Pink Pony PeptidesOnline sellerMar 31, 2026Unapproved New Drugs Sold Over the Internet
The letter’s words: “Food and Drug Administration (FDA) reviewed your website at https://pinkponypeptides.com/ in December 2025.”
fda.gov
pppepz.comPeak Performance PeptidesNot statedAug 24, 2026Unapproved New Drugs/Misbranded
The letter’s words: “FDA Review Violations were identified and documented during a review of your website pppepz.com in July 2026.”
fda.gov
premiumhealth.usPremium Health Management Inc. dba Premium HealthTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://premiumhealth.us, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
prime-sciences.comPrime SciencesOnline sellerMar 31, 2026Unapproved New Drugs Sold Over the Internet
The letter’s words: “Food and Drug Administration (FDA) reviewed your website at https://prime-sciences.com/ from January to March 2026.”
fda.gov
primepeptides.coPrime Vitality, Inc. dba Prime PeptidesNot statedDec 10, 2024Unapproved New Drugs/Misbranded
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https://primepeptides.co in October 2024 and has observed that your website offers various products as “peptides” including, “Semaglutide” and “Retatrutide.” We …”
fda.gov
readymednow.comReady MedTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Ready Med’s website, https://readymednow.com, FDA Establishment Identifier (FEI) 3044868483, in May 2026.”
fda.gov
refills.comRefills Health, LLC dba Refills HealthTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.refills.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide drug products.”
fda.gov
remedymeds.comRemedy MedsTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://remedymeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
resetiv.comReset IV, LLC dba Reset IVTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://resetiv.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
roenrx.comRoen Health, Inc. dba RoenRxTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of RoenRx’s website, https://roenrx.com, FDA Establishment Identifier (FEI) 3044022969, in March 2026.”
fda.gov
ronanrx.comRonanRx, Inc. dba RonanRxTelehealthOct 30, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of RonanRx’s website, https://ronanrx.com and associated social media platforms, FDA Establishment Identifier (FEI) 3048890334, in September 2026.”
fda.gov
royal-peptides.comRoyal Peptides LLCNot statedAug 24, 2026Unapproved New Drugs/Misbranded
The letter’s words: “FDA Review Violations were identified and documented during a review of your website royal-peptides.com in July 2026.”
fda.gov
rxmadesimple.comSimpleRxTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://rxmadesimple.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
sema.bioSemaBioTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://sema.bio in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
semaspace.comwww.semaspace.comNot statedOct 2, 2023Finished Pharmaceuticals/Unapproved New Drug/Misbranded
The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.semaspace.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …”
fda.gov
skinnyrx.comLean Rx, Inc. dba SkinnyRxTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://skinnyrx.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
skool.comMile High Compounds LLCOnline sellerMar 31, 2026Unapproved New Drugs Sold Over the Internet
The letter’s words: “Food and Drug Administration (FDA) reviewed your website at https://milehighcompounds.is, which links to your community forum www.skool.com/milehighcompoundsofficial/, from January to March 2026.”
fda.gov
slendid.comSlendidTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://slendid.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
struthealth.comStrut Health, LLC dba StrutTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.struthealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
summitpeptides.shopSummit Research PeptidesNot statedDec 10, 2024Unapproved New Drugs/Misbranded
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https://summitpeptides.shop in October 2024 and has observed that your website offers “Semaglutide” (or “Sema”), “Retatrutide” (or “Reta”), “Cagrilintide,” …”
fda.gov
texpeptide.comTXP Innovations LLC dba Tex PeptidesNot statedAug 24, 2026Unapproved New Drugs/Misbranded
The letter’s words: “FDA Review Violations were identified and documented during a review of your website texpeptide.com in July 2026.”
fda.gov
thehcginstitute.comThe HCG InstituteTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://thehcginstitute.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
thelyferx.comLyfe RxTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://thelyferx.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
thrivelab.comThrivelab Co. dba ThrivelabTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Thrivelab’s website, https://www.thrivelab.com, FDA Establishment Identifier (FEI) 3043997633, in March 2026.”
fda.gov
tryamie.comAmie Health, Inc. dba AmieTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Amie Health, Inc.’s website, https://tryamie.com, FDA Establishment Identifier (FEI) 3044000672, in March 2026.”
fda.gov
tryeden.comEden Health International Inc. dba EdenTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of Eden’s website, https://www.tryeden.com, FDA Establishment Identifier (FEI) 3044020039, in March 2026.”
fda.gov
trygenesis.comGenesis Health International Inc. dba GenesisTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.trygenesis.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
trymeasured.comBetter Health Labs, Inc. dba MeasuredTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://trymeasured.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
trymhealth.comTRYM Health, Inc. dba TRYM HealthTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://trymhealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
trynovamd.comTry NovaTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://trynovamd.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.”
fda.gov
tuyohealth.comTuyo Health, Inc. dba Tuyo HealthTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.tuyohealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
usapeptide.comUSApeptide.comNot statedFeb 26, 2025Unapproved New Drugs/Misbranded
The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.usapeptide.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …”
fda.gov
uschemlabs.comUS Chem LabsNot statedFeb 7, 2024CGMP/Finished Pharmaceuticals/Adulterated
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address www.uschemlabs.com in October 2023 and has observed that your website offers “Semaglutide,” “Tirzepatide” and “Thymalin” products for sale in the United States.”
fda.gov
villashealth.comLas Villas Health Care LLC dba Villas HealthTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://villashealth.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and sildenafil.”
fda.gov
vitalsrx.comVitals RXTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://vitalsrx.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
viviomd.comVivioMD Group LLC dba VivioMDTelehealthJun 8, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “FDA Review Violations were identified and documented during a review of VivioMD’s website, https://viviomd.com, FDA Establishment Identifier (FEI) 3044027316, in March 2026.”
fda.gov
vivrx.comViv Health, Inc. dba VIV RXTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.vivrx.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.”
fda.gov
weightcrunchshop.comwww.weightcrunchshop.comOnline sellerJan 13, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet
The letter’s words: “… is to advise you that the United States (U.S.) Food and Drug Administration (FDA) recently reviewed your website at the Internet address www.weightcrunchshop.com and has observed that your website introduces into interstate commerce misbranded and unapproved new drugs in violation of sections 301(a), …”
fda.gov
xcelpeptides.comXcel Research LLCNot statedDec 10, 2024Unapproved New Drugs/Misbranded
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the internet address https://www.xcelpeptides.com in October 2024 and has observed that your website offers various products such as “RETA” (Retatrutide), “CagriLean” (Cagrilintide and …”
fda.gov
ybycmeds.comybycmedsTelehealthSep 9, 2025Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://ybycmeds.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide and tirzepatide.”
fda.gov
zappyhealth.comKare Solutions, LLC dba ZappyTelehealthFeb 20, 2026False & Misleading Claims/Misbranded (Telehealth)
The letter’s words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://zappyhealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide, tirzepatide, and liraglutide drug products.”
fda.gov

Each letter is addressed to the firm in the second column, not to the website. The quoted sentence is the letter’s own reference to the site.

Common questions

Does an FDA warning letter name tryeden.com?

Yes. FDA’s warning letter dated Jun 8, 2026 is addressed to Eden Health International Inc. dba Eden, not to the website. It refers to the site in these words: “FDA Review Violations were identified and documented during a review of Eden’s website, https://www.tryeden.com, FDA Establishment Identifier (FEI) 3044020039, in March 2026.” The FDA subject line is “False & Misleading Claims/Misbranded (Telehealth).”

Does an FDA warning letter name ivimhealth.com?

Yes. FDA’s warning letter dated Feb 20, 2026 is addressed to Ivim Services LLC dba Ivim, not to the website. It refers to the site in these words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.ivimhealth.com, in December 2025, and has observed that your website offers compounded drug products, including semaglutide and tirzepatide drug products.” The FDA subject line is “False & Misleading Claims/Misbranded (Telehealth).”

Does an FDA warning letter name hims.com?

Yes. FDA’s warning letter dated Sep 9, 2025 is addressed to Hims & Hers Health, Inc. dba Hims, not to the website. It refers to the site in these words: “This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website content at the internet address https://www.hims.com in August 2025 and has observed that your website offers various compounded drug products, including semaglutide.” The FDA subject line is “Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth).”

Why are some brands not on this list?

This list covers websites named in FDA warning letters that name a GLP-1 drug. A brand that has not received such a letter does not appear, and this site does not create pages for companies without a public record.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.